Claims for Patent: 8,106,021

Summary for Patent: 8,106,021

Title:	Benzylbenzene derivatives and methods of use
Abstract:	Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
Inventor(s):	Chen Yuanwei, Cheng Huawei, Li Shengbin, Wu Yuelin, Feng Yan, Lv Binhua, Xu Baihua, Seed Brian, Hadd Michael J., Song Yanli, Du Jiyan, Wang Congna, Roberge Jacques Y.
Assignee:	Theracos, Inc.
Application Number:	US12917367
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,106,021
Patent Claims:	2. The method of claim 1 , wherein said disease or condition is type 1 diabetes mellitus.3. The method of claim 1 , wherein said disease or condition is type 2 diabetes mellitus.4. The method of claim 1 , wherein said disease or condition is obesity.5. The method of claim 1 , wherein said compound is administered in combination with a second therapeutic agent.6. The method of claim 5 , wherein said second therapeutic agent is selected from the group consisting of antidiabetic agents claim 5 , lipid-lowering/lipid-modulating agents claim 5 , agents for treating diabetic complications claim 5 , anti-obesity agents claim 5 , antihypertensive agents claim 5 , antihyperuricemic agents claim 5 , and agents for treating chronic heart failure or atherosclerosis.7. The method of claim 6 , wherein said antidiabetic agent is selected from the group consisting of insulin and insulin mimetics claim 6 , sulfonylureas claim 6 , insulin secretion enhancers claim 6 , biguanides claim 6 , sulfonylurea/ biguanide combinations claim 6 , meglitinides claim 6 , thiazolidinediones claim 6 , thiazolidinedione/ biguanide combinations claim 6 , oxadiazolidinediones claim 6 , PPAR-gamma agonists claim 6 , PPAR-alpha/gamma dual agonists claim 6 , PPAR-alpha/gamma/delta pan agonists claim 6 , retinoid X receptor agonists claim 6 , alpha-glucosidase inhibitors claim 6 , stimulants of insulin receptor tyrosine kinase claim 6 , tripeptidyl peptidase II inhibitors claim 6 , dipeptidyl peptidase IV inhibitors claim 6 , protein tyrosine phosphatase-1B inhibitors claim 6 , glycogen phosphorylase inhibitors claim 6 , glucose-6-phosphatase inhibitors claim 6 , fructose 1 claim 6 ,6-bisphosphatase inhibitors claim 6 , pyruvate dehydrogenase inhibitors claim 6 , imidazoline derivatives claim 6 , hepatic gluconeogenesis inhibitors claim 6 , D-chiroinositol claim 6 , glycogen synthase kinase-3 inhibitors claim 6 , incretin mimetics claim 6 , GLP-1 claim 6 , GLP-1 analogs claim 6 , GLP-1 receptor agonists claim 6 , amylin claim 6 , amylin analogs and agonists claim 6 , aP2 inhibitors claim 6 , beta-3 adrenergic receptor agonists claim 6 , and other insulin sensitivity enhancers.8. The method of claim 7 , wherein said sulfonylurea is selected from the group consisting of glibornuride claim 7 , gliclazide claim 7 , glimepiride claim 7 , glipizide claim 7 , gliquidone claim 7 , glisoxepide claim 7 , glyburide claim 7 , and glyclopyramide.9. The method of claim 7 , wherein said biguanide is metformin.10. The method of claim 7 , wherein said meglitinide is selected from the group consisting of repaglinide claim 7 , nateglinide claim 7 , and mitiglinide.11. The method of claim 7 , wherein said thiazolidinedione is selected from the group consisting of rosiglitazone claim 7 , pioglitazone claim 7 , and CLX-0921.12. The method of claim 7 , wherein said alpha-glucosidase inhibitor is selected from the group consisting of acarbose and miglitol.13. The method of claim 7 , wherein said dipeptidyl peptidase IV inhibitor is selected from the group consisting of sitagliptin claim 7 , saxagliptin and vildagliptin.14. The method of claim 7 , wherein said incretin mimetic is exenatide.15. The method of claim 7 , wherein said GLP-1 analog is liraglutide.16. The method of claim 7 , wherein said amylin analog is pramlintide.17. The method of claim 6 , wherein said anti-obesity agent is selected from the group consisting of serotonin-norepinephrine reuptake inhibitors claim 6 , norepinephrine-dopamine reuptake inhibitors claim 6 , selective serotonin reuptake inhibitors claim 6 , selective norepinephrine reuptake inhibitors claim 6 , norepinephrine releasing stimulants claim 6 , anorexiants claim 6 , dopamine agonists claim 6 , H-histamine antagonists claim 6 , 5-HT2c receptor agonists claim 6 , beta-3 adrenergic receptor agonists claim 6 , cholecystokinin agonists claim 6 , antidepressant/acetylcholinesterase inhibitor combinations claim 6 , lipase inhibitors claim 6 , anti-epileptic agents claim 6 , leptin claim 6 , leptin analogs and leptin receptor agonists claim 6 , NPY receptor antagonists and modulators claim 6 , ciliary neurotrophic factor claim 6 , thyroid hormone receptor-beta agonists claim 6 , cannabinoid CB1 receptor antagonists claim 6 , melanin-concentrating hormone receptor antagonists claim 6 , melanocortin-4 receptor agonists claim 6 , selective muscarinic receptor Mantagonists claim 6 , opioid receptor antagonists claim 6 , and combinations thereof.18. The method of claim 17 , wherein said norepinephrine-dopamine reuptake inhibitor is bupropion.19. The method of claim 17 , wherein said selective serotonin reuptake inhibitor is selected from the group consisting of citalopram claim 17 , escitalopram claim 17 , fluoxetine claim 17 , fluvoxamine claim 17 , paroxetine claim 17 , and sertraline.20. The method of claim 17 , wherein said anorexiant is phentermine.21. The method of claim 17 , wherein said anti-epileptic agent is topiramate.22. The method of claim 17 , wherein said selective muscarinic receptor Mantagonist is telenzepine.23. The method of claim 17 , wherein said opioid receptor antagonist is naltrexone.